Please login to the form below

Not currently logged in
Email:
Password:

Antibody drug conjugates

This page shows the latest Antibody drug conjugates news and features for those working in and with pharma, biotech and healthcare.

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Company specialises in antibody-drug conjugate development. German pharma company Boehringer Ingelheim has announced that it will acquire all shares of NBE-Therapeutics for a total of 1.18bn. ... NBE-Therapeutics, headquartered in Switzerland, is

Latest news

More from news
Approximately 7 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    Antibody-drug conjugates. New regimes have evolved that help extend the amount of time patients have without their condition worsening. ... One such example is through the development of antibody-drug conjugates (ADC) – monoclonal antibodies attached

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    it into a drug candidate with commercial potential and taking it all the way to market with strong financing and sound management. ... In addition to traditional antibodies, the pipeline also includes antibody drug conjugates (ADCs), bispecific

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    Current projects include developing antibodies for use as cancer imaging agents, antibody drug conjugates, chimeric antigen receptor therapies (CAR-Ts) and nano-medicines. ... and using efficient AI to generate a set of high-quality drug candidates.

  • Deal Watch February 2016 Deal Watch February 2016

    $26m Series A financing. The antibody, to be known as COR-001, will be progressed for cardiovascular applications. ... This month saw two existing partnerships that have been extended. Takeda has been working with Mersana Therapeutics since 2014 to

  • Pharma deals in April 2015 Pharma deals in April 2015

    The agreement also includes payment of double digit royalties.  . Innate also put in place a collaboration with Sanofi for next generation antibody-drug conjugates (ADCs) using Innate's site specific conjugation ... its SAR3419, an antibody-drug

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

  • Crescendo Biologics appoints Peter Pack as CEO Crescendo Biologics appoints Peter Pack as CEO

    Crescendo is now shifting its focus to oncology with novel VH-based checkpoint modulators and humabody drug conjugate (HDC) therapeutics. ... We intend to expand rapidly our internal oncology programmes on checkpoint modulators and HDCs, which are a

  • ADC Therapeutics expands team ADC Therapeutics expands team

    Appointments preceed its first antibody drug conjugate trials. ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Oncology drug development company's new team

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    These programmes focus on antibody-drug conjugates (ADCs) to target cancers. The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.

  • AVEO's financial head joins ImmunoGen AVEO's financial head joins ImmunoGen

    In his new role, Johnston will head the financial operations of one of the leading biotechs working to develop antibody-drug conjugates in cancer, with ImmunoGen's successes including the breast

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    CytomX Therapeutics has boosted both its senior science and business teams following a major antibody deal with Pfizer. ... Both positions will be crucial to supporting the San Francisco-based biotech's  growth following CytomX's  $635m deal agreed

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics